$DCTH

Delcath Systems (DCTH) announced presentations at ESMO Congress 2026, including updates on its Phase 2 trials for metastatic colorectal and breast cancer. Independent data on its CHEMOSAT system for liver-dominant metastatic uveal melanoma showed a 66.7% objective response rate and 28-month median overall survival. The company focuses on liver cancer treatments with its HEPZATO KIT and CHEMOSAT systems.

An independent analysis of 12 patients with liver-metastatic uveal melanoma treated with melphalan hepatic delivery (PHP) and ipilimumab/nivolumab reported a 66.7% response rate and 75% disease control rate. The median overall survival was 28 months. Delcath Systems, Inc. is presenting clinical trial updates at ESMO Congress 2026, including data on its HEPZATO KIT and CHEMOSAT systems for liver-directed chemotherapy.

Delcath Systems (DCTH) reported Q2 revenue of $29.1M, up from $24.2M YoY, driven by its HEPZATO KIT and CHEMOSAT devices. The company raised its 2026 revenue guidance to $104M-$108M. However, expenses rose, with R&D and SG&A increasing, leading to flat net income. Delcath has $95.9M in cash and no debt, and is expanding into new indications.

DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interven

Delcath Systems (Nasdaq: DCTH) said the first patient was dosed in its Phase 2 DELUMA trial of HEPZATO plus standard of care versus standard of care alone for liver-dominant HER2-negative metastatic breast cancer. The randomized study will enroll about 90 patients at 20+ sites in the US and Europe, with hepatic progression-free survival as the primary endpoint.

Delcath Systems announced new data from a retrospective analysis on percutaneous hepatic perfusion with melphalan (M-PHP) using the CHEMOSAT Hepatic Delivery System for liver-dominant metastatic breast cancer. The data, presented at the ESMO Breast Cancer Congress 2026, showed hepatic partial response in 60% of evaluable patients and highlighted safety considerations like blood transfusions and transient bone marrow suppression. This real-world evidence supports further evaluation of HEPZATO KIT and CHEMOSAT in this heavily pretreated patient population.

Delcath Systems, Inc., a microcap biopharmaceutical company, has seen its valuation grade shift from attractive to expensive due to changing financial metrics, despite reporting positive pre-tax and net profit growth over the past five quarters. The company faces a complex financial landscape with negative EV to EBIT and EV to EBITDA ratios, and its stock's technical trend has moved to mildly bearish. This re-evaluation highlights the evolving financial dynamics for Delcath Systems within the competitive biotechnology sector.

Investors need to pay close attention to Delcath Systems stock based on the movements in the options market lately.

Delcath Systems (DCTH) delivered earnings and revenue surprises of 0.00% and +0.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Delcath Systems Inc ( NASDAQ:DCTH ) rose sharply in pre-market trading after the company announced preliminary third quarter 2025 financial results. The company's Phase 2 CHOPIN study achieved primary endpoint, with PHP plus immunotherapy extending median PFS to 12.8 months versus ...